The mission of the Bioinformatics Share Resource (BISR) is to provide cutting edge bioinformatics services and collaborative research support to MCCC investigators engaged in genomics studies with high impact on the care of cancer patients. The allied BISR led by Dr. Jean-Pierre Kocher currently counts 7 MS and Ph.D. level allied health bioinformaticians. The service lines offered by the BIC fall in 4 categories: i) preprocessing of omics data including several workflow dedicated to Next Generation Sequencing data analysis, ii) data annotation services critical for the first level interpretation of preprocessed genomics data, iii) data management solution for the integration of large genomics, proteomics and metabolomics datasets iv) data collection services from internal and external data sources (Mayo Biobank, TCGA, GEO, etc.). The BISR also facilitates the collaborative research opportunity between MCCC faculty and Bioinformatics Faculty. The BISR has forged a tight patnership with the Research IT Department for the development of Bioinformatics workflows and systems. About 10 analysts programmers of the Research IT department are supporting the BISR at no additional charge to MCCC. Over the last 5 years, the BISR has worked with 121 MCCC investigators on more than 775 projects. About 60% of these investigators had or have peer reviewed funding. The BISR has faciliated the collaborative engagement of more than 13 bioinformatics faculty on 39 projects led by MCCC investigators. During the same period, BISR faculty and allied health staff were coauthor on over 75 publications during the project period with MCCC investigators. In addition, over the last year, BSIR faculty were listed as key personal on more than 60 submitted grants. BSIR faculty are engaged with the Prostate, Breast, Lymphoma and Ovarian Spores. In the future, the BISR will pursue the development of preprocessing workflows, further implement or develop methods for the advanced interpretation of omics data as well as maintain its educational activities. BISR is now located on all 3 Mayo sites: Mayo Clinic Rochester (MCR), Mayo Clinic Arizona (MCA), and Mayo Clinic Florida (MCF).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications